NCT05518578Phase 2Recruiting

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

Study sponsor: Supernus Pharmaceuticals, Inc. · SUPN

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-12-31Estimated

Enrollment · participants60Estimated

Source updated2026-04-21Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-04-21 · 2 fields changed

Enrollment · participant count

Recorded edit

− Previous value

count: 35; type: ESTIMATED

+ Updated value

count: 60; type: ESTIMATED

Primary completion date

Recorded edit

− Previous value

2024-10

+ Updated value

2027-12-31

Check registry source